Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.51 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604634 | 0.93 | DRD2 (0.51) | DRD2TBXA2RPTGES2TBXAS1SLC2A1 | |
| SCHEMBL1605126 | 0.90 | TP53 (0.47) | DRD2TBXA2RPTGES2TBXAS1SLC2A1 | |
| SCHEMBL1606572 | 0.89 | PTGES2 (0.52) | PTGES2TBXAS1PPARG | |
| Hydrochloric Acid SCHEMBL11006604 | 0.89 | PTGES2 (0.51) | PTGES2TBXAS1PPARG | |
| SCHEMBL1605499 | 0.88 | SLC2A1 (0.44) | DRD2TBXA2RPTGES2TBXAS1SLC2A1 | |
| SCHEMBL1606087 | 0.87 | TBXAS1 (0.45) | TBXAS1SLC2A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL1606033 | 0.84 | TP53 (0.47) | DRD2TBXA2RPTGES2TBXAS1SLC2A1 | |
| SCHEMBL1604760 | 0.83 | CCR2 (0.51) | PTGES2TBXAS1PPARG | |
| SCHEMBL1604861 | 0.83 | ALDH1A1 (0.45) | PTGES2TBXAS1CYP11B1CYP11B2MAPT | |
| SCHEMBL1606934 | 0.82 | DRD2 (0.49) | DRD2TBXA2RTBXAS1SLC2A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | claimed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8030334-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| EP-2307371-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082129-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | DRD2 2487/4885TBXA2R 1079/4885PTGES2 474/4885 |
| US-20100261698-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | DRD2 2487/4885TBXA2R 1079/4885PTGES2 474/4885 |
| US-20150210672-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | DRD2 2471/4885TBXA2R 1076/4885PTGES2 538/4885 |
| US-20140288126-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | DRD2 2471/4885TBXA2R 1076/4885PTGES2 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.